Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Verve Therapeutics Inc
(NQ:
VERV
)
5.520
+0.410 (+8.02%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Verve Therapeutics Inc
< Previous
1
2
Next >
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Verve Therapeutics, Inc. – VERV
Today 16:19 EDT
From
Rosen Law Firm
Via
Business Wire
Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 01, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
June 28, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 31, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Leadership Update
May 31, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics to Participate in Upcoming Investor Conferences
May 30, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
May 08, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
May 07, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
Verve Therapeutics
Via
GlobeNewswire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
April 02, 2024
From
Schall Law
Via
GlobeNewswire
Verve Therapeutics Announces Updates on its PCSK9 Program
April 02, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 28, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 01, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement
December 01, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
November 28, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
November 28, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia
November 12, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3
October 31, 2023
Lilly Purchases Product Rights to Verve’s Lead Cardiovascular Programs from Beam Therapeutics
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia
October 23, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association’s Scientific Sessions 2023
September 26, 2023
Company to hold investor event in conjunction with data presentation on November 12, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
September 21, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer
September 18, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results
August 10, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference
August 03, 2023
From
Verve Therapeutics
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.